The global erythropoietin (EPO) drugs market size was valued at USD 7.4 billion in 2016 and is expected to witness CAGR of 11.5% during the forecast period. Increasing incidence of chronic diseases such as end-stage renal diseases, cancer, and HIV is expected to accelerate demand for EPO-stimulating agents as these diseases may cause anemia. To curb rising incidence of anemia, demand for erythropoietin drugs is expected to increase over the coming years.
One of the major reasons for anemia is Chronic Kidney Diseases (CKD). Rising incidence of CKD is the key contributing factor responsible for the growing demand. According to statistics published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 661,000 people are affected by kidney failures in the U.S. and the number is projected to increase in the near future. This is anticipated to fuel the demand for the market further.
U.S. erythropoietin drugs market revenue by drug class, 2014 - 2025 (USD billion)
Patent expiration of major biologics during the coming years creates opportunities for the entry of erythropoietin biosimilars in the market. For instance, Amgen’s patent for Epogen expired in 2015, which offered tremendous opportunities for other companies to enter the industry. Hence, it is expected that there will be an increase in the number of new entrants investing in the market, leading to growth.
The prevalence rate of cancer, HIV, and CKD in developing countries is high, which serves as an important opportunity for drug manufacturers to expand their presence in this market. There is an increased demand for low-cost therapeutics in developing countries such as Asia Pacific and Middle East &Africa, which has triggered the production of biosimilars for EPOs in such regions. Growing utilization of biosimilar EPOs is anticipated to boost the growth of overall EPO market in the coming years.
Of the various drug classes, biologics erythropoietin class held a dominant share as of 2016, owing to patent protection. Presence of large patient population and higher uptake of biologics are other contributing factors towards its dominance. In addition, availability of very few biologics in the market has led to the increased adoption. Furthermore, owing to its wide applications in the treatment of CKD, the biologics segment accounted for the majority of revenue share.
The biologics segment is anticipated to lose its market share due to recent patent expiration of major brands such as Epogen. This drug lost its patent exclusivity in May 2015, which resulted in reduced sales revenue for its manufacturer company, Amgen Inc.
Biosimilars are expected to gain popularity in the near future for the treatment of anemic conditions. Biosimilars are easy to develop, cost-effective, and require less time for approval as compared to biologics. These associated advantages are expected to propel the segment growth throughout the forecast period.
Increasing investments in R&D for biosimilars, strong product pipeline, and collaborations between hospitals &manufactures for the adoption of EPO biosimilars are key market drivers for the growth of the biosimilar segment. The recent launch of erythropoietin biosimilars in the U.S. is further expected to showcase paradigm shift in global EPO drugs from biologics to biosimilars.
In the product segment, Epoetin-alfa held a dominant share due to its wide adoption amongst healthcare professionals. This product was the first biologic to be approved by the U.S.FDA for treatment of anemia resulting from CKD, cancer chemotherapy, and HIV treatment. Epoetin-alfa was patent protected, which restricted the production of any other recombinant human erythropoietin drug and helped this segment dominate in 2016.
Epoetin-beta is a recombinant form of epoetin-alfa. This segment held a considerable share in the products segment owing to its benefits such as improved efficacy and longer half-life in comparison with epoetin-alfa. NeoRecormon, developed by F. Hoffman-La Roche, is the first drug containing epoetin-beta as the active ingredient.
Darbepoetin-alfa is yet another novel erythropoietin drug developed by Amgen, Inc., which is marketed under the brand name Aranesp. The patent for this drug expires in 2024 in the U.S. Until this period, this drug enjoys patent exclusivity rights in the U.S. In Europe, patent for Aranesp expired in 2016, due to which the sales of this drug have decreased in this region.
Darbepoetin-alfa is anticipated to witness positive growth in future due to its cost-effectiveness, improved efficacy, and longer half-life. This is a viable solution for the treatment of anemia rising from end-stage renal diseases. Research is being undertaken for the discovery of new therapeutic areas for the application of darbepoetin-alfa, which is expected to serve this industry with growth potential.
Other medication such as epoetin-zeta and epoetin-omega are expected to exhibit lucrative growth rate in coming years. These are biosimilar formulations of epoetin-alfa but are more effective in the treatment of anemic conditions. EporatiobyTeva Pharmaceutical Industries, Ltd. and Mircera by F. Hoffmann-La Roche Ltd. are major products in this segment.
Renal diseases held a dominant share as prevalence of anemiais increasing at a constantrate. The first erythropoietin drug, Epogen was approved by the U.S. FDA for the treatment of anemic indications arising from CKD. Owing to early introduction of this drug for the treatment of CKD and rising incidence of the same, this segment dominated as of 2016.
The cancer segment is expected to be the fastest growing segment owing to the increasing number of cancer incidence worldwide. Cancer chemotherapy involves use of medication that reduce the RBC count amongst patients. As a result, usage of these alongside chemotherapy has become common in the recent years. This has resulted in increasing demand of EPO drugs for cancer treatment, which augments growth.
The hematology segment is anticipated to witness steady growth over the forecast period due to rising R&D initiatives to develop cost-effective and viable solutions for treating conditions such as hypoxia and anemia of prematurity. Proper dosage of recombinant human erythropoietin can cure anemia of prematurity and reduces the need of multiple blood transfusion in neonates. This is expected to serve this industry with growth potential.
The neurology segment is expected to showcase growth over the forecast period as many of the erythropoietin drugs are considered to be an effective solution for treating neurological disorders such as the Parkinson’s disease. Companies are involved in discovering new therapeutic areas for application of erythropoietin-stimulating agents, apart from treatment of anemia. Major therapeutic research is being carried out for the neurology segment.
North America held a considerable share of erythropoietin drugs as of 2016 owing to increasing incidence of chronic diseases such as cancer, CKD and HIV. According to the Centers for Disease Control and Prevention (CDC), 1.2 million people in the U.S. are living with HIV and 39,513 cases were diagnosed in 2015. These statistics indicate the need for EPO drugs over the forecast period.
In order to satisfy unmet needs, favorable reimbursement policies for HIV treatment are developed by the U.S. government. This would in turn provide a healthy platform for the growth of the North American EPO market. Furthermore, owing to patent expiration of biologics, numerous new players have entered the market in this region and are undertaking various strategic steps to gain more revenue share. For instance, in October 2016, Teva Pharmaceutical Industries Ltd. acquired Anda, Inc., a leading distributor of generics in the U.S. from Allergan, plc., thereby strengthening its distribution network.
Global erythropoietin drugs market revenue, by application, 2016 (%)
The Asia Pacific EPO industry is anticipated to grow at the fastest CAGR due to continuous rise in incidence of chronic diseases coupled with high demand for low-cost therapeutics. Asia Pacific has attracted significant interest of many companies for the development of biosimilars and is known for developing more biosimilars, than anywhere else in the globe.
Moreover, increasing government initiatives to provide better health amenities to public in this region is another contributing factor for market growth. For instance, the Japanese government has passed a regulation to price biosimilars at a discount of 30%in comparison to make it available to people belonging to lower economic class at subsidized prices.
The major companies in this industry are Johnson & Johnson; Celltrion, Inc.; Teva Pharmaceutical Industries Ltd.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; LG Life Sciences Ltd.; Biocon Limited; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.; and Dr. Reddy’s Laboratories Ltd.
This industry is witnessing significant growth owing to patent expiration of biologics. This has attracted several local and international players to invest in the production of erythropoietin drugs. The key factor responsible for the rising participation of various companies is to cater to the growing demand for anemia treatment.
The industry is competitive in nature with key players involved in continuous product development and partnership alliances to aid market penetration. Rising number of distributors and dealers are also expected to elevate industry rivalry in the near future.
Industry players are involved in extensive R&D activities. Many biosimilar products are under clinical trials in the U.S. & Europe, which are expected to gain approval over the coming years. Thus, owing to the aforementioned factors, competitive rivalry for this market is expected to be high throughout the forecast period.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, UK, Germany, Japan, China, India, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global erythropoietin drugs market on the basis of drug class, product, application, and region:
Drug Class Outlook (Revenue, USD Million, 2014 - 2025)
Product Outlook (Revenue, USD Million, 2014 - 2025)
Application Outlook (Revenue, USD Million, 2014 - 2025)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
The Middle East and Africa
b. The global erythropoietin (EPO) drugs market is expected to grow at a compound annual growth rate of 11.5% from 2017 to 2025 to reach USD 17.4 billion by 2025.
b. North America dominated the erythropoietin (EPO) drugs market with a share of 43.5% in 2019. This is attributable to increasing awareness about chronic diseases and its treatment, favorable reimbursement policies, and the high presence of major players.
b. Some key players operating in the erythropoietin (EPO) drugs market include Johnson & Johnson; Celltrion, Inc.; Teva Pharmaceutical Industries Ltd.; Amgen, Inc.; F. Hoffmann-La Roche Ltd.; LG Life Sciences Ltd.; Biocon Limited; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.; and Dr. Reddy’s Laboratories Ltd.
b. Key factors that are driving the market growth include the introduction of new erythropoietin drugs, increasing incidence of chronic diseases, and increasing R&D activities for the development of novel drugs.
b. The global erythropoietin (EPO) drugs market size was estimated at USD 8.0 billion in 2019 and is expected to reach USD 8.8 billion in 2020.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.